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Abstract 
Introduction: In this study of preclinical Alzheimer’s disease (AD) we assessed the added 
diagnostic value of using cerebrospinal fluid (CSF) Aβ ratios rather than Aβ42 in isolation for 
detecting individuals who are positive on amyloid positron emission tomography (PET). 
Methods: Thirty-eight community-recruited cognitively intact older adults (mean age 73, range 
65-80 years) underwent 18F-flutemetamol PET and CSF measurement of Aβ1-42, Aβ1-40, 
Aβ1-38, and total tau (ttau). 18F-flutemetamol retention was quantified using standardized 
uptake value ratios in a composite cortical region (SUVRcomp) with reference to cerebellar grey 
matter. Based on a prior autopsy validation study, the SUVRcomp cut-off was 1.57. Sensitivities, 
specificities and cut-offs were defined based on receiver operating characteristic analysis with 
CSF analytes as variables of interest and 18F-flutemetamol positivity as the classifier. We also 
determined sensitivities and CSF cut-off values at fixed specificities of 90% and 95%. 
Results: Seven out of 38 subjects (18%) were positive on amyloid PET. Aβ42/ttau, Aβ42/Aβ40, 
Aβ42/Aβ38, and Aβ42 had the highest accuracy to identify amyloid-positive subjects (area 
under the curve (AUC) ≥ 0.908). Aβ40 and Aβ38 had significantly lower discriminative power 
(AUC = 0.571). When specificity was fixed at 90% and 95%, Aβ42/ttau had the highest 
sensitivity among the different CSF markers (85.71% and 71.43%, respectively). Sensitivity of 
Aβ42 alone was significantly lower under these conditions (57.14% and 42.86%, respectively). 
Conclusion: For the CSF-based definition of preclinical AD, if a high specificity is required, 
our data support the use of Aβ42/ttau rather than using Aβ42 in isolation. 
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Introduction 
Preclinical [1,2], or asymptomatic [3], Alzheimer’s disease (AD) is characterized by the 
presence of AD-related pathophysiological processes in the absence of cognitive deficits. 
Evidence of brain amyloidosis is a requirement common to all 3 National Institute on Aging and 
Alzheimer’s Association (NIA-AA) stages of preclinical AD [1] and is also a defining feature of 
the asymptomatic at-risk for AD state according to the International Working Group (IWG-2) 
criteria [3]. This can be detected directly in vivo by means of either β-amyloid (Aβ) protein 
quantification in cerebrospinal fluid (CSF) or positron emission tomography (PET) amyloid 
imaging [1],[3]-[5]. 
Apart from Aβ1-42, other Aβ isoforms (e.g. Aβ1-40, Aβ1-38) have evoked interest from a 
clinical-diagnostic perspective, as either a separate biomarker tool or when combined (ratio) 
with Aβ1-42 [6]-[8]. Using ratios of Aβ isoforms (Aβ1-42/Aβ1-38, Aβ1-42/Aβ1-40) may have 
added value for the discrimination between AD and normal pressure hydrocephalus [9], cerebral 
amyloid angiopathy [10], frontotemporal dementia [11], and Lewy body dementia [12], and also 
between mild cognitive impairment (MCI) due to AD versus non-AD MCI [13]. In cognitively 
intact individuals, Aβ38 or Aβ40 do not correlate with amyloid PET positivity, in contrast with 
Aβ42 [5],[14]. 
In this study of preclinical AD, we assessed the added value of using ratios of Aβ42 to other C-
terminal Aβ isoforms or to total tau for discriminating amyloid-positive versus amyloid-negative 
cognitively intact healthy controls, with an autopsy-validated 18Fflutemetamol cut-off score [15]
as standard-of-truth. The cut-off value was derived from the 18F-flutemetamol phase 3 study 
using a binarized measure of postmortem brain neuritic plaque density [16]
 
(overall mean 
Bielschowsky score below or above 1.5 [15]). We also explored the diagnostic value of the 
Aβ38 and Aβ40 isoforms on their own.  
For design of clinical trials in preclinical AD, the data presented may inform the decision which 
CSF parameter to select for study eligibility based on its equivalence to an amyloid-PET based 
definition. We not only provide the parameters providing optimal balance between sensitivity 
and specificity but also the parameters that provide an acceptable sensitivity for a fixed high 
specificity. Specificity may receive more weight in trials in preclinical AD as the definition of 
!    4
the target population often heavily relies on the biomarker value, healthy volunteers are exposed 
to potential adverse effects of study drugs for a long duration, and positive evidence for the 
presence of the study target increases the likelihood of success. Sensitivity will mainly 
determine the number needed to screen, and therefore impact on the cost. 
Methods 
Participants 
Thirty-eight cognitively intact older controls (mean age 73 years, SD 5 years, Table 1) were 
prospectively and consecutively recruited, from September 10th 2012 until April 4th 2014, 
through advertisement in local newspapers and through websites for seniors, asking for healthy 
volunteers between 65 and 80 years of age for participation in a scientific study at the University 
Hospital Leuven, Belgium, involving brain imaging (sic). At screening, subjects underwent a 
detailed interview about medical history, a Mini Mental State Examination (MMSE), a Clinical 
Dementia Rating (CDR), blood sampling, and a conventional neuropsychological assessment. 
Inclusion criteria were age 65 - 80 years, MMSE ≥ 27, CDR = 0, and normal test scores on 
neuropsychological assessment according to the published norms adapted for age, gender, and 
education. Among the exclusion criteria were a neurological or psychiatric history and focal 
brain lesions on structural magnetic resonance image (MRI). Subjects who fulfilled all criteria 
underwent both 18Fflutemetamol PET and lumbar puncture. The target sample size of the PET-
plus-CSF cohort was 40 but two subjects dropped out after the PET scan and prior to the lumbar 
puncture, giving a final sample size of 38. 
This PET-plus-CSF cohort belonged to a larger cohort of healthy older controls undergoing 18F-
flutemetamol PET (target sample n = 180, recruited until time of writing n = 172) [17],[18]. The 
other subjects of this larger cohort did not undergo lumbar puncture per protocol. The primary 
aim of the full cohort was to investigate the interaction between BDNF and APOE genetic 
polymorphisms on amyloid deposition and functional reorganisation [17], [18]. The in- and 
exclusion criteria for the full cohort were identical to that of the PET-plus-CSF cohort apart 
from the age range (50 - 80 years for the full cohort). At inclusion, participants of the full cohort 
were stratified per age bin for two genetic factors: Brain-Derived Neurotrophic Factor (BDNF) 
(met allele at codon 66 present or absent) and Apolipoprotein E (APOE) (ε4 allele present or 
absent). The cells of this 2 x 2 factorial design were prospectively matched for number of cases, 
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APOE and BDNF genetic status, age, sex, and education. 
APOE = Apolipoprotein E; MMSE = Mini Mental State Examination; AVLT = Rey Auditory Verbal 
Learning Test; TL = total learning; DR = delayed recall; BNT = Boston Naming Test; AVF = Animal 
Verbal Fluency Test; LVF = Letter Verbal Fluency Test; RPM = Raven’s Progressive Matrices; TMT = 
Trail Making Test part B divided by part A; ttau = total tau. 
The PET-plus-CSF cohort (n = 38) did not differ from the remaining subjects (n = 134) with 
regards to sex, education, number of APOE ε4 carriers or BDNF met carriers, the presence of 
subjective memory complaints (29% in each of the two groups), or neuropsychological test 
scores (P > 0.23). The CSF cohort was significantly older than the remaining subjects (mean age 
73 years vs mean age 67 years, P < 0.0001).  The proportion of amyloid-positive cases did not 
differ significantly between the CSF-plus-PET cohort (18%) and the remaining subjects (12%) 
(P = 0.23).  
The protocol (EudraCT: 2009-014475-45) was approved by the Ethics Committee University 
Hospitals Leuven. Written informed consent was obtained from all subjects in accordance with 
the Declaration of Helsinki. 
Amyloid PET 
18F-flutemetamol PET was acquired on a 16-slice Siemens Biograph PET/CT scanner (Siemens, 
Erlangen, Germany). The tracer was injected as a bolus in an antecubital vein (mean activity 150 
Table 1 Demographics and CSF biomarkers concentrations [mean (SD, range)]
Gender (male/female) 22/16 LVF (# words) 36.0 (10.8, 17-64)
Age (years) 73 (4.7, 65-80) RPM (/60) 36.1 (9.8, 15-53)
Education (years) 13.4 (3.1, 8-20) TMT B/A 2.4 (0.5, 1.5-3.8)
APOE ε4 carriers (n) 19 (50%) Aβ38 (pg/mL) 2401 (654, 1057-3505)
BDNF met carriers (n) 20 (53%) Aβ40 (pg/mL) 8933 (2456, 3640-13273)
MMSE (/30) 28.9 (1.0, 27-30) Aβ42 (pg/mL) 996 (430, 351-1859)
AVLT TL (/75) 46.2 (8.4, 31-69) ttau (pg/mL) 360 (134, 126-660)
AVLT DR (/15) 9.8 (2.5, 5-14) Aβ42/Aβ38 0.412 (0.119, 0.136-0.596)
AVLT %DR 83.7 (11.7, 55-108) Aβ42/Aβ40 0.110 (0.030, 0.044-0.148)
BNT (/60) 54.2 (4.2, 41-60) Aβ42/ttau 3.015 (1.246, 0.749-5.128)
AVF (# words) 24.0 (5.5, 14-40) Amyloid+ (n) 7 (18%)
    !    6
MBq, SD 5 MBq, range 134-162 MBq). Scan acquisition started 90 min after tracer injection 
and lasted for 30 min [17]-[20]. Prior to PET acquisition, a low-dose computed tomography 
scan of the head was performed for attenuation correction. Random and scatter correction were 
applied. The PET summed image was spatially normalized to Montreal Neurological Institute 
(MNI) space using a fully automated PET-only method [21]. On the basis of spatially 
normalized images (voxel size 2 x 2 x 2 mm3) standard uptake value ratios (SUVR) were 
calculated with cerebellar grey matter as reference region. Mean SUVR value was calculated in 
a composite cortical region (SUVRcomp) [15]. The composite cortical region and the cerebellar 
grey matter reference region were defined as a combination of narrow automated anatomic 
labeling-type regions [22]
 
outlined on the ICBM-152 template masked with a grey matter 
probability mask [15]. Images were analyzed by an experienced medical imaging specialist 
blinded to all study information. 
To estimate the SUVRcomp cut-off for detecting amyloid-positivity in vivo using the above 
described method, a receiver operating curve (ROC) analysis has been performed by Thurfjell et 
al. (2014) on an independent dataset of 68 SUVRcomp values (quantified based on the above 
described method) with the autopsy results as a standard-of-truth [15]. The autopsy data were 
classified following Vemuri’s modification of the Consortium to Establish a Registry for AD 
criteria [16],[23]. Eight cortical regions (precuneus, midfrontal cortex, superior temporal cortex, 
middle temporal cortex, inferior parietal cortex, anterior cingulate gyrus, posterior cingulate 
gyrus, and primary visual cortex) were scored using an overall mean Bielschowsky score: 0 = 0 
plaques, 1 = 1-5 plaques, 2 = 6-19 plaques, 3 ≥ 20 plaques. If the mean Bielschowsky score was 
> 1.5 in at least one region, the brain was classified as amyloid-positive, if all regions had ≤ 1.5, 
the brain was classified as amyloid-negative. The resulting SUVRcomp cut-off was 1.57 [15]. 
Lumbar puncture and CSF analysis 
Lumbar punctures were carried out at the L4/5 level in the morning (10 am – 2 pm) and 
collected in a polypropylene tubes (Greiner Bio-one Cellstar, VWR, Leuven, Belgium, total 
volume 15 mL), with discarding 1 mL to avoid traumatic blood contamination. Samples were 
centrifuged within 30 min after collection (2600 RPM, 10 min, 4˚C). After centrifugation, 
supernatants were transferred in polypropylene tubes and from there aliquoted in 1.5 mL 
polypropylene tubes (Kartell, Noviglio, Italy, volume CSF/tube 1 mL). Samples were stored at 
    !    7
80˚C until batch analysis. Our primary analysis was based on the EUROIMMUN single analyte 
enzyme-linked immunosorbent assays (ELISA) (EUROIMMUN, Lübeck, Germany) of CSF 
Aβ1-42, Aβ1-40, Aβ1-38, and total tau (ttau). The assays were performed at ADx Ghent by two 
experienced laboratory technicians blinded to all study information. The Aβ assays quantify the 
full length of the C-terminus-specific Aβ isoforms (Aβ1-specific assay format). The tau assay is 
designed with a capture antibody towards the central region and one monoclonal antibody with 
an epitope at the amino-terminus of the protein. The assay design includes lyophylised 
recombinant proteins as calibrators, run-validation control samples (= calibrators added to a 
phosphate-buffered solution), as well as a qualification panel to evaluate the analytical 
performance(s) in the lab. These novel immunoassays are free from matrix interference and their 
intra-assay reproducibility has a coefficient of variation (CV) ≤ 5.0% with an inter-assay 
reproducibility ≤ 8.3% [24].  
As a secondary analysis, we verified our results using the INNOTEST ELISA for Aβ1-42, ttau 
and 181phospho-tau (ptau) (Fujirebio Europe, Ghent, Belgium). The assays were performed at 
the laboratory medicine department of UZ Leuven in a ISO-15189 and Joint Commission 
International accredited environment by an expert technician blinded to all study information. 
The assay design included ready to use recombinant proteins as calibrators, run-validation 
control samples, and internal quality controls samples (of which target value and acceptance 
criteria were established in the routine setting of AD biomarker quantification).   
Statistical analysis 
In the primary analysis, which was based on the EUROIMMUN assays, we compared 
diagnostic accuracy of different CSF Aβ isoforms, their ratios, ttau and Aβ42/ttau to detect 
amyloid-positive older individuals. We used a ROC analysis with CSF analytes as variables of 
interest and 18F-flutemetamol positivity defined based on autopsy-derived SUVRcomp cut-off as a 
classifier. We also evaluated whether case classification changed when we varied the cut-off by 
± 1.5%, corresponding to the test-retest variability estimated for SUVRcomp [20]. The highest 
Youden index (sensitivity + specificity - 1) was used to estimate the optimal ROC cut-offs. 
Statistical differences between ROC curves were evaluated according to the method of DeLong 
et al. [25]
 
for pairwise ROC comparisons. Correction for multiple comparisons (n = 21) was 
performed with Bonferroni method. Bonferroni corrected threshold for significance was P < 
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0.002 corresponding to P corrected < 0.05. 
Depending on the study, a high specificity may be desirable even if this implies a loss of 
sensitivity. We therefore also evaluated sensitivities and cut-offs at a fixed prespecified 
specificity of 90% and 95%, respectively. We evaluated whether this changed case classification 
significantly (McNemar test). 
As a secondary analysis, we performed ROC analyses based on the INNOTEST assay of Aβ42, 
total tau and 181phospho-tau and statistically compared the AUCs between the two types of 
assays. We also compared the AUCs between the different INNOTEST measures and 
determined sensitivity and percentage of correct classifications at a fixed specificity of 90 and 
95%.  
As a further secondary analysis, we evaluated the continuous relationship between the different 
CSF analytes and 18F-flutemetamol SUVRcomp values. We tested whether a linear, polynomial 
(quadratic), exponential or hyperbolic relation fitted best to these data. The model assumptions 
were assessed by evaluating normality and homoscedasticity of residuals with q-q plots and 
plots of residuals versus fitted values. The best fitting model was selected based on Akaike 
information criterion (AIC) which is a measure of model fit. A lower AIC indicates a better fit. 
CSF analytes were used as dependent variables and 18F-flutemetamol SUVRcomp as an 
independent variable. 
Statistical analyses were performed in R version 3.1.1 (https://www.r-project.org) and MedCalc 
version 14.8.1 (https://www.medcalc.org). 
Results 
Based on the autopsy-confirmed 18F-flutemetamol SUVRcomp cut-off, 7 out of 38 subjects (18%) 
were assigned to the amyloid-positive category (Figure 1A). Case assignment did not change 
when we varied the cut-off according to the known test-retest replicability. 
APOE ε4 carriers had significantly lower values of Aβ42, Aβ42/ttau, Aβ42/Aβ40, and Aβ42/
Aβ38 than ε4 non-carriers (P < 0.003). CSF analytes’ concentrations did not differ between 
BDNF met carriers and non-carriers (P > 0.23).  
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Figure 1. Distribution of 18F-flutemetamol SUVRcomp values and ROC curves for different CSF analytes. 
(A) Distribution of 18F-flutemetamol SUVRcomp values according to age, sex, and APOE genotype. Solid 
line = 1.57 SUVRcomp cut-off, dashed lines = 1.57 SUVRcomp cut-off ± 1.5% corresponding to a test-retest 
variability for SUVRcomp [20] (1.594 and 1.547). (B) ROC curves for different CSF analytes, with 18F-
flutemetamol positivity as classifier. Dots represent optimal cut-offs for each analyte, corresponding to 
the highest Youden index. 
Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38, and Aβ42 discriminated between 18F-flutemetamol positive 
and negative subjects with high accuracy (AUC ≥ 0.908, Table 2, Figure 1B). Aβ38, Aβ40, and 
ttau showed a lower discriminative power with AUC ≤ 0.724 (Table 2). Aβ42/ttau, Aβ42/Aβ40, 
and Aβ42 had significantly higher AUCs than Aβ38 or Aβ40 alone (Table 2, P < 0.003). Aβ42/
Aβ38 had significantly higher AUCs than Aβ40 (P = 0.002). There was no significant difference 
between ratios Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38 on the one hand and Aβ42 alone, on the 
other hand (Table 2, P > 0.32). The AUCs of the three ratios were not statistically different from 
each other (Table 2, P > 0.30).  
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Analyte concentrations are described as pg/mL or calculated as ratios between concentrations of two 
analytes. Statistically significant differences of AUCs between analytes are indicated by * and †. *P 
corrected < 0.05 compared with Aβ40. †P corrected < 0.05 compared with Aβ38. No other differences of 
AUCs were found. aCut-off corresponding to the highest Youden index. bPercentage of positively 
classified cases based on the CSF cut-off compared with amyloid PET classification. AUC = area under 
the ROC curve, SE = standard error, CI = confidence interval. 
When specificity was fixed at 90%, Aβ42/ttau and Aβ42/Aβ40 had the highest sensitivity and 
Aβ42/Aβ38 the second highest sensitivity (Table 3). All three Aβ isoforms (Aβ42, Aβ40, Aβ38) 
used on their own detected significantly fewer amyloid PET positive cases when specificity was 
fixed a priori at 90% than when the cut-off was based on the highest Youden index (Table 3), 
indicative of a significant loss in sensitivity. This was not the case for Aβ42/ttau, Aβ42/Aβ40, 
Aβ42/Aβ38 ratios, and ttau (Table 3). 
When specificity was fixed at 95%, Aβ42/ttau had the highest sensitivity (Table 3). All Aβ 
isoforms, ttau, and all ratios detected significantly less amyloid-positive cases when the 
specificity was fixed a priori at 95% compared to the highest Youden index based cut-off, with 
one exception namely the ratio Aβ42/ttau (Table 3). At a specificity of 95%, the number of 
amyloid PET positive cases detected based on the ratio Aβ42/ttau did not differ significantly 
from the number detected based on the highest Youden index based cut-off, although it was 
numerically lower. 
Table 2 Diagnostic performance of different CSF analytes with 18F-flutemetamol PET as 
autopsy validated standard-of-truth (EUROIMMUN assay)
AUC SE 95% CI Cut-offa Sensitivity (%)
Specificity 
(%)
Correctly 
classifiedb (%)
Aβ38 0.571 0.111 0.401-0.730 2909 100 32.26 45
Aβ40 0.571 0.112 0.401-0.730 10738 100 29.03 42
Aβ42*† 0.908 0.051 0.769-0.977 745 100 74.19 79
ttau 0.724 0.148 0.555-0.856 436 71.43 80.65 76
Aβ42/Aβ38* 0.935 0.039 0.806-0.989 0.332 100 87.10 89
Aβ42/Aβ40*† 0.954 0.033 0.832-0.995 0.096 100 80.65 84
Aβ42/ttau*† 0.963 0.028 0.846-0.998 2.006 100 87.10 89
    !    11
Analyte concentrations are described as pg/mL or calculated as ratios between concentrations of two 
analytes. aPercentage of subjects who were classified differently based on the cut-offs from fixed 
specificities compared with the cut-offs corresponding to the highest Youden index (Table 2). 
bSignificance for the “Difference”. cPercentage of positively classified cases based on the CSF cutoffs 
from fixed specificities compared with amyloid PET classification. CI = confidence interval. 
As a secondary analysis, we compared the AUCs between two types of assays, EUROIMMUN 
and INNOTEST. The AUCs for Aβ42, ttau and Aβ42/ttau did not differ between EUROIMMUN 
and INNOTEST assays (Aβ42 P = 0.33, ttau P = 0.91 and Aβ42/ttau P = 0.25) (Table 2 vs 4). 
When we compared the AUCs between the different INNOTEST measures, the AUC for Aβ42/
ttau differed significantly from the AUC for ttau (uncorrected P = 0.0172) or ptau (uncorrected P 
= 0.0096). When specificity was fixed at 90%, Aβ42 and Aβ42/ttau had the highest sensitivity 
(Table 4). When specificity was fixed at 95%, Aβ42/ttau had the highest sensitivity (Table 4). 
Table 3 Clinical accuracy: estimated sensitivities and cut-off values at a fixed specificity of 90% or 
95% (EUROIMMUN assay)
Sensitivity 
(%) 95% CI Cut-off
Differencea 
(%) P value
b Correctly 
classifiedc (%)
Specificity of 90%
Aβ38 14.29 0.00-71.43 1446 65.79 <0.0001 79
Aβ40 14.29 0.00-71.43 5602 65.79 <0.0001 76
Aβ42 57.14 0.00-100.00 546 21.05 0.008 84
ttau 57.14 14.29-100.00 471 10.53 0.125 82
Aβ42/Aβ38 71.43 0.00-100.00 0.268 7.89 0.250 87
Aβ42/Aβ40 85.71 14.29-100.00 0.074 10.53 0.125 89
Aβ42/ttau 85.71 14.29-100.00 1.852 5.26 0.500 89
Specificity of 95%
Aβ38 14.29 0.00-71.43 1342 68.42 <0.0001 82
Aβ40 14.29 0.00-71.43 5254 71.05 <0.0001 82
Aβ42 42.86 0.00-85.71 493 28.95 0.001 87
ttau 42.86 0.00-85.71 539 18.42 0.016 84
Aβ42/Aβ38 28.57 0.00-71.43 0.251 21.05 0.008 84
Aβ42/Aβ40 57.14 8.62-85.71 0.067 21.05 0.008 89
Aβ42/ttau 71.43 28.57-100.00 1.415 13.16 0.063 92
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Analyte concentrations are described as pg/mL or calculated as ratios between concentrations of two 
analytes. aCut-off corresponding to the highest Youden index. bPercentage of positively classified cases 
based on the CSF cut-off compared with amyloid PET classification. cPercentage of subjects who were 
classified differently based on the cut-offs from fixed specificities compared with the cut-offs 
corresponding to the highest Youden index. dSignificance for the “Difference”. AUC = area under the 
ROC curve, SE = standard error, CI = confidence interval. 
Four CSF analytes, Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38, and Aβ42, showed a significant 
correlation with the 18F-flutemetamol SUVRcomp values (Figure 2). The linear model was 
rejected because it did not satisfy assumptions of the model. The hyperbolic model fitted best to 
the relationship between Aβ42 and 18F-flutemetamol SUVRcomp. The relationships between 18F-
flutemetamol SUVRcomp and Aβ42/ttau, Aβ42/Aβ40, Aβ42/Aβ38 were best described by the 
exponential model. However, differences between the models were small. There was no 
correlation between 18F-flutemetamol SUVRcomp values and Aβ38, Aβ40, and ttau (Figure 2). 
Table 4 Diagnostic performance of different CSF analytes measured with INNOTEST assay 
for Aβ42, ttau, and ptau at an optimal specificity and at a specificity fixed at 90% or 95%
AUC SE 95% CI Cut-offa Sensitivity (%)
Specificity 
(%)
Correctly 
classifiedb (%)
Aβ42 0.935 0.0394 0.806-0.989 853 100 83.87 87
ttau 0.733 0.132 0.565-0.863 352 71.43 77.42 76
ptau 0.675 0.139 0.504-0.818 86 42.86 93.55 84
Aβ42/ttau 0.880 0.0878 0.734-0.963 2.258 85.71 90.32 89
Specificity of 
90% Sensitivity (%) 95% CI Cut-off
a Differencec 
(%) P value
d Correctly 
classifiedb (%)
Aβ42 85.71 11.54-100.00 798 7.90 0.25 89
ttau 57.14 14.29-100.00 465 10.53 0.125 82
ptau 42.96 0.00-85.71 87 5.26 0.5 79
Aβ42/ttau 85.71 28.57-100.00 2.263 0 1 89
Specificity of 
95% Sensitivity (%) 95% CI Cut-off
a Differencec 
(%) P value
d Correctly 
classifiedb (%)
Aβ42 42.86 4.05-100.00 672 21.05 0.008 87
ttau 14.29 0.00-85.71 566 23.69 0.004 82
ptau 28.57 0.00-71.43 94 2.63 1 82
Aβ42/ttau 71.43 8.71-100.00 2.093 7.90 0.25 92
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Figure 2. Associations between the different CSF analytes and 18F-flutemetamol SUVRcomp. 
Black lines represent fitting of the model, shown only for the significant correlations. 
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Discussion 
Overall, when sensitivity and specificity were combined, the ability to discriminate amyloid-
positive from amyloid-negative cognitively healthy older adults was comparable between Aβ42 
on its own and the ratio of Aβ42 over the isoforms examined or over total tau. However, when a 
high specificity of 90 - 95% was imposed as a criterion, the sensitivity of Aβ42 alone 
diminished to 43 - 57%. The sensitivity of the ratio over Aβ40 was acceptable at specificity of 
90% (86%) but at 95% it decreased to 57%. Under these requirements, the ratio over total tau 
was the only measure which retained an acceptable sensitivity (71 - 86%). A high specificity 
would for instance be desirable if the potential benefit of a study drug depends on the amyloid-
positivity of cognitively normal subjects and the study drug has potentially noxious effects or a 
high cost. A favorable trade-off in terms of sensitivity, as was the case only for Aβ42 over total 
tau, would decrease the number of subjects needed to scan to reach a prespecified number of 
positive cases. 
Added value of Aβ isoforms Aβ38 and Aβ40 
The shorter isoforms Aβ38 and Aβ40 on their own had no diagnostic value to discriminate 
preclinical AD, in line with previous studies in cognitively intact healthy controls [14], and also 
in clinical AD patients [26]. In the context of preclinical AD, the added value of the Aβ isoforms 
mainly occurred when used for calculating ratios. The ratio over Aβ40 performed better than 
Aβ42 alone if a high specificity was required (Table 3). 
The impact of using Aβ isoforms on the clinical accuracy is linked in part to the context of use. 
In some studies comparing clinical AD with healthy controls, the ratio of Aβ42 over Aβ38 or 
Aβ40 improved overall diagnostic accuracy [27],[28], but in others it did not [26],[29]. For the 
discrimination between clinically probable AD and non-AD dementias, the discriminative value 
of Aβ42/Aβ40 was similar to that of the ratio over total tau and better than Aβ42 alone [30],[31]. 
In the MCI stage of the disease, the predictive value for progression to dementia over a 4 year 
interval was higher for Aβ42/Aβ40 (AUC = 0.866) than for Aβ42 alone (AUC = 0.768) [13]. In 
our study, Aβ42/Aβ40 still allowed acceptable sensitivity for a specificity of 90%, and more so 
than Aβ42 in isolation. 
The reason why ratios perform better than Aβ42 in isolation may be methodological: the 
normalization procedure may remove a portion of the pre-analytical and analytical variability in 
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the measurement of the protein levels that is in itself unrelated to AD. In that case, as better 
standards will become available for Aβ42 measurement, the benefit of using ratios will 
diminish. Alternatively, the ratio may perform better than Aβ42 for biological reasons. Many 
autosomal dominant forms of AD are associated with an increase in the ratio of Aβ42 over Aβ40 
[32],[33]. Others, such as the Dutch and the Arctic APP mutation, are associated with the inverse 
effect [32]. If the driving force in the initial phases of sporadic AD is related to a disequilibrium 
between different isoforms rather than the absolute amount of Aβ42 on its own, this could 
theoretically explain why the ratio would be better. 
Ratio of Aβ42 over total tau 
For a fixed specificity of 95%, the highest sensitivity (71%) was obtained for Aβ42 over total 
tau. Total tau is generally thought to reflect neuronal loss. Adding the separate measurement of a 
biomarker that increases with the intensity of the neurodegenerative process may enhance 
specificity because AD is a multidimensional disease [34],[35]
 
so that adding a second 
dimension (neuronal loss) improves accuracy of classification. The added value of combining 
Aβ42 with ttau for the definition of preclinical AD is in line with the IWG-2 criteria for 
preclinical AD which advocate for the combined use of both Aβ42 and ttau or ptau [3]. 
CSF cut-off for positive classification 
The optimal Aβ42 cut-off for the INNOTEST assay was higher than what is commonly applied 
in clinical practice. Previous studies have also suggested that cut-offs derived from studies in 
patients with more or less advanced stages of Alzheimer’s disease versus controls may not be 
entirely appropriate for distinguishing amyloid-positive from amyloid-negative healthy 
cognitively intact older adults [14],[36]. This has implications for clinical trials aiming to 
sensitively select cognitively intact subjects with increased Aβ aggregation [36]. 
Potential study limitations 
Our study has some limitations. The sample size was relatively low and the number of amyloid-
positive cases relatively small. Larger studies of preclinical AD will be needed to confirm the 
estimates of sensitivity and specificity. The low sample size is related to the strict inclusion and 
exclusion criteria. All subjects were recruited from the community and volunteered for the 
lumbar puncture purely for research purposes and were informed beforehand that they would 
not receive any feedback about their proper CSF results. We also applied strict criteria regarding 
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the normality of the neuropsychological test scores. Given the small sample size we were 
careful to base our conclusions on the most robust findings: We applied strict correction for 
multiple comparisons and ascertained that our findings were replicable across different assay 
types and did not depend on small variations of the PET cut-off within the range of the known 
test-retest variability of 18F-flutemetamol PET. For all these reasons we consider our results 
reliable despite the relatively small sample size, in particular the comparisons between AUC 
analyses. The repercussions of fixing specificity at 90 - 95% on sensitivity have to be interpreted 
more cautiously: Given the relatively low number of true positives, a change in classification of 
an individual case from positive to negative may lead to a disproportionately large decrease in 
sensitivity. 
A community-recruited cohort is not equivalent to a population-based cohort and could be prone 
to a selection bias, targeting subjects concerned about their cognition, subjects who were more 
educated or more mobile, etc.  We were careful not to mention memory, cognition or related 
terms in our advertisement. The research question at hand, namely the comparison between CSF 
and PET for the research definition of preclinical AD, is most pertinent for a community-
recruited setting: Clinical trials targeting preclinical AD will generally not be based on 
population-based nor on memory clinic based cohorts but on community-recruited cohorts. 
There was no evidence for a positive selection bias compared to other community-recruited 
cohorts. If anything, also taking into account the prior stratification for APOE ε4 in our study, 
our percentage of amyloid-positive cases was lower than in most other community-recruited 
studies [37]. In a population-based cross-sectional study of cognitively intact 50 - 89 years old 
adults, the frequency of amyloid-positive individuals was similar to that in our study [38]. The 
proportion of subjects who confirmed subjective memory complaints was also not particularly 
elevated compared with community- [39],[40] or population-based studies [41].  
Our standard-of-truth was 18F-flutemetamol positivity based on an autopsy-validated cut-off. We 
have previously demonstrated a high concordance between 18F-flutemetamol and 11C-Pittsburgh 
Compound B for the definition of preclinical AD [42]. The autopsy study covered the different 
Thal stages 1-5 [43]. However, it remains possible, theoretically, that if measured in a 
population restricted to cognitively intact older adults, the cut-off for distinguishing moderate to 
high neuritic amyloid density from sparse to low density may be lower than what is found in a 
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mixed group including patients with advanced dementia along with dementia-free individuals 
[43]. According to the current study logic, a case who has low Aβ42 values but a normal 18F-
flutemetamol value would be considered a false-positive. We, however, cannot exclude that this 
case is in a preclinical state preceding amyloid deposition detectable by PET [14]. In the 
selection of subjects who have increased risk of amyloid deposition but who have not yet 
reached the amyloid positivity threshold, there could still be a role for Aβ isoforms beyond 
Aβ42, though this remains to be demonstrated. The specificity required to define preclinical AD 
based on biomarkers will depend on the type of clinical trial. Different therapeutic strategies 
may target different preclinical stages of the disease. Our findings are mainly relevant for those 
trials that target a phase where amyloid aggregation has already occurred and where a marker 
must be selected, CSF versus amyloid PET. 
Conclusion 
For selection of subjects with increased PET amyloid load, if a high specificity is required, our 
data support the use of Aβ42 over total tau rather than using Aβ42 alone or the ratios to other Aβ 
isoforms. 
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